HK1029526A1 - Nkt cell-activating agents containing alpha-glycosylceramides - Google Patents
Nkt cell-activating agents containing alpha-glycosylceramidesInfo
- Publication number
- HK1029526A1 HK1029526A1 HK01100286A HK01100286A HK1029526A1 HK 1029526 A1 HK1029526 A1 HK 1029526A1 HK 01100286 A HK01100286 A HK 01100286A HK 01100286 A HK01100286 A HK 01100286A HK 1029526 A1 HK1029526 A1 HK 1029526A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- glycosylceramides
- nkt cell
- activating agents
- agents containing
- containing alpha
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 239000004015 abortifacient agent Substances 0.000 abstract 1
- 231100000641 abortifacient agent Toxicity 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9241297 | 1997-04-10 | ||
PCT/JP1998/001657 WO1998044928A1 (en) | 1997-04-10 | 1998-04-10 | NKT CELL ACTIVATORS CONTAINING α-GLYCOSYLCERAMIDES |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1029526A1 true HK1029526A1 (en) | 2001-04-06 |
Family
ID=14053712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01100286A HK1029526A1 (en) | 1997-04-10 | 2001-01-11 | Nkt cell-activating agents containing alpha-glycosylceramides |
Country Status (13)
Country | Link |
---|---|
US (2) | US6531453B1 (id) |
EP (2) | EP1520583B1 (id) |
JP (1) | JP3495740B2 (id) |
KR (1) | KR100527950B1 (id) |
CN (2) | CN1768759A (id) |
AT (2) | ATE421881T1 (id) |
CA (1) | CA2286482C (id) |
DE (2) | DE69840528D1 (id) |
ES (2) | ES2318236T3 (id) |
HK (1) | HK1029526A1 (id) |
ID (1) | ID23495A (id) |
TW (1) | TW592703B (id) |
WO (1) | WO1998044928A1 (id) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE421881T1 (de) * | 1997-04-10 | 2009-02-15 | Kyowa Hakko Kirin Co Ltd | Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten |
TW575420B (en) * | 1997-09-22 | 2004-02-11 | Kirin Brewery | Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides |
FR2792205B1 (fr) * | 1999-04-19 | 2001-07-27 | Inst Nat Sante Rech Med | Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie |
SE0000258D0 (sv) * | 2000-01-27 | 2000-01-27 | A & Science Invest Ab | Pharmaceutical preparation and method for treatment of diabetes |
US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
US20040009594A1 (en) * | 2000-06-06 | 2004-01-15 | Hiro Wakasugi | Method for amplifying natural killer t cells |
US20020115624A1 (en) * | 2000-06-22 | 2002-08-22 | Behar Samuel M. | Alpha gylcosylceramides for treating bacterial and fungal infections |
JPWO2002038146A1 (ja) * | 2000-11-07 | 2004-03-11 | 株式会社林原生物化学研究所 | 粘膜免疫調節剤並びにその用途 |
EP1372668B1 (en) * | 2001-03-26 | 2011-12-07 | Dana-Farber Cancer Institute, Inc. | Method of attenuating reactions to skin irritants |
WO2003009812A2 (en) * | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
BR0211968A (pt) | 2001-08-16 | 2004-09-28 | Daiichi Suntory Pharma Co Ltd | Glicolipìdio útil no tratamento de doenças autoimunes e medicamento do mesmo |
EP1444330A1 (en) * | 2001-11-07 | 2004-08-11 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
US6911434B2 (en) * | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
FR2839310A1 (fr) * | 2002-05-03 | 2003-11-07 | Pasteur Institut | Nouveau procede de preparation d' alpha-glycosylceramides, nouveaux derives alpha-glycosylceramide et leurs applications |
CA2493690C (en) * | 2002-06-13 | 2011-11-08 | New York University | Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases |
US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
US20060116331A1 (en) * | 2002-09-27 | 2006-06-01 | Biomira, Inc. | Glycosylceramide analogues |
EP1585508B1 (en) | 2003-01-20 | 2009-04-01 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for reducing plasma cholesterol and triacylglycerol levels |
NL1022443C2 (nl) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipiden voor verbetering van de samenstelling van de darmflora. |
ES2450043T3 (es) | 2003-02-14 | 2014-03-21 | Japan As Represented By President Of National Center Of Neurology And Psychiatry Ministry Of Healt | Derivados del glicolípido, proceso para su producción, intermedios para la síntesis del mismo, y proceso para la producción de los intermedios |
WO2005032462A2 (en) | 2003-02-27 | 2005-04-14 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20040171522A1 (en) * | 2003-02-27 | 2004-09-02 | Yaron Ilan | Regulation of immune responses by manipulation of intermediary metabolite levels |
US9717754B2 (en) | 2003-02-27 | 2017-08-01 | Enzo Therapeutics, Inc. | Glucocerebroside treatment of disease |
US20060239979A1 (en) * | 2003-03-03 | 2006-10-26 | Kirin Beer Kabushiki Kaisha | Dendritic cell presenting a-glycosylceramide derivative and antigent and usable in suppressing immune response |
US7645873B2 (en) | 2003-03-20 | 2010-01-12 | The Scripps Research Institute | 6″-amino-6″-deoxygalactosylceramides |
US7771726B2 (en) * | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
CA2526905A1 (en) * | 2004-02-19 | 2005-09-01 | Kibun Food Chemifa Co., Ltd. | Composition for nkt cell activation |
EP1576894A1 (en) * | 2004-03-16 | 2005-09-21 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome |
US20070207983A1 (en) * | 2004-03-16 | 2007-09-06 | Nieuwenhuizen Willem F | Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome |
US20050222048A1 (en) * | 2004-03-31 | 2005-10-06 | The Research Foundation Of The City University Of New York | Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases |
EP1767216B1 (en) | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
US8022043B2 (en) * | 2004-08-27 | 2011-09-20 | Albert Einstein College Of Medicine Of Yeshiva University | Ceramide derivatives as modulators of immunity and autoimmunity |
JP5226311B2 (ja) * | 2004-08-27 | 2013-07-03 | アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ | 免疫及び自己免疫の調節因子としてのセラミド誘導体 |
DE602005020643D1 (de) * | 2004-09-03 | 2010-05-27 | Univ Chicago | Verfahren zur aktivierung von nkt-zellen |
US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
KR101243577B1 (ko) * | 2004-10-07 | 2013-03-20 | 아고스 쎄라퓨틱스, 인코포레이티드 | 성숙 수지상 세포 조성물 및 그의 배양 방법 |
JP4948418B2 (ja) | 2004-11-02 | 2012-06-06 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Nkt細胞を抑制するための方法 |
US7906488B2 (en) | 2004-11-30 | 2011-03-15 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
US7923013B2 (en) | 2004-12-28 | 2011-04-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NKT cells |
WO2006071848A2 (en) * | 2004-12-28 | 2006-07-06 | The Rockefeller University | Glycolipids and analogues thereof as antigens for nk t cells |
DK1848813T3 (da) | 2005-01-28 | 2013-07-15 | Univ Brigham Young | Aktivering af bakterielt glycolipid fra CD1D-begrænsede NKT-celler |
US8173608B2 (en) | 2005-03-04 | 2012-05-08 | Riken | Compound having cyclic structure and use thereof |
JP4909264B2 (ja) * | 2005-04-01 | 2012-04-04 | 独立行政法人理化学研究所 | 経鼻ワクチン |
CA2613350A1 (en) * | 2005-07-01 | 2007-01-11 | Japan As Represented By President Of National Center Of Neurology And Ps Ychiatry | Glycolipid derivative and drug containing the same as active component |
JP2007070311A (ja) * | 2005-09-09 | 2007-03-22 | Gunma Univ | α−ガラクトシルセラミドからなる感染症予防剤及び感染症治療剤 |
US20090117089A1 (en) * | 2005-09-19 | 2009-05-07 | The Rockefeller University | Glycolipids and analogues thereof as antigens for nk t cells |
JP2009513646A (ja) | 2005-10-25 | 2009-04-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | α‐ガラクトシルセラミドのアナログ及びその使用 |
US20070231344A1 (en) * | 2005-10-28 | 2007-10-04 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
BRPI0618024A2 (pt) * | 2005-10-28 | 2011-08-16 | Japan Government | fármaco terapêutico para supressão de funções de células nkt o qual contém derivado de glicolipìdeo como ingrediente ativo |
JP5126684B2 (ja) * | 2006-02-28 | 2013-01-23 | 独立行政法人理化学研究所 | 新規糖脂質及びその用途 |
EP2056842B1 (en) | 2006-04-07 | 2012-10-17 | The Scripps Research Institute | Modified-galactosyl ceramide for the treatment of cancerous diseases |
IL178821A0 (en) * | 2006-05-25 | 2007-07-04 | Ilan Yaron | Direct and indirect modulation of composition and structure of cell membrane by ??-glycolipids |
WO2008005824A1 (en) * | 2006-06-30 | 2008-01-10 | The Scripps Research Institute | Adjuvants and methods of use |
US8263576B2 (en) * | 2006-08-15 | 2012-09-11 | Mayo Foundation For Medical Education And Research | Non-natural sphingolipid analogs and uses thereof |
KR100868959B1 (ko) | 2006-12-30 | 2008-11-17 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는면역보조용 약학적 조성물 |
JP5357782B2 (ja) | 2007-02-21 | 2013-12-04 | バクシネックス インコーポレーティッド | 抗原負荷CD1d分子によるNKT細胞活性の調節 |
JP5504891B2 (ja) * | 2007-02-22 | 2014-05-28 | 独立行政法人理化学研究所 | 新規擬似糖脂質及びその用途 |
US8916164B2 (en) | 2007-08-29 | 2014-12-23 | Abivax | Methods of enhancing adjuvaticity of vaccine compositions |
EP2058011A1 (en) | 2007-11-07 | 2009-05-13 | Wittycell | Nkt cell activating gycolipids covalently bound antigens and/or drug |
EP2060252A1 (en) | 2007-11-19 | 2009-05-20 | Wittycell | New formulation of galactosylceramide derivatives |
EP2231145B1 (en) | 2007-12-05 | 2014-09-17 | Wittycell | Use of glycosylceramides for enhancing the immune response to antigens |
WO2009119692A1 (ja) * | 2008-03-25 | 2009-10-01 | 独立行政法人理化学研究所 | 新規糖脂質及びその用途 |
CA2739765A1 (en) | 2008-10-08 | 2010-04-15 | Vincent Serra | Vaccine composition for use against influenza |
KR20110137290A (ko) * | 2009-01-08 | 2011-12-22 | 알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 | 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도 |
EP2532671B1 (en) | 2010-02-05 | 2014-09-17 | Riken | Novel synthetic glycolipid and use thereof |
US8835613B2 (en) | 2010-03-12 | 2014-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | β-mannosylceramide and stimulation of NKT cell anti-tumor immunity |
US10813950B2 (en) | 2010-12-02 | 2020-10-27 | Riken | Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells |
JP6192120B2 (ja) | 2012-04-26 | 2017-09-06 | 国立研究開発法人理化学研究所 | 新規カルバメート糖脂質およびその用途 |
EP2889039B1 (en) | 2012-08-22 | 2017-11-08 | Regimmune Corporation | Preparation for preventing or treating type i diabetes |
WO2014053482A1 (en) * | 2012-10-03 | 2014-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza with invariant nkt cell agonists |
CA2889858A1 (en) | 2012-11-05 | 2014-05-08 | Regimmune Corporation | Immune-tolerance inducer |
AU2013349706B2 (en) | 2012-11-21 | 2019-08-22 | Assistance Publique - Hopitaux De Paris | Methods for determining the risk of acute graft versus host disease |
US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
CN105339379B (zh) | 2013-02-08 | 2019-11-26 | 瓦克纳斯有限公司 | 改性的糖脂及其制备和使用方法 |
WO2014178195A1 (ja) | 2013-05-02 | 2014-11-06 | 独立行政法人産業技術総合研究所 | 糖鎖抗原の免疫誘導剤 |
US20170029454A1 (en) * | 2013-06-28 | 2017-02-02 | The Scripps Research Institute | Nkt cell ligands and methods of use |
JP6494594B2 (ja) * | 2014-02-26 | 2019-04-03 | 国立大学法人北海道大学 | 樹状細胞を含有する医薬およびその製造方法 |
US10709758B2 (en) | 2015-09-03 | 2020-07-14 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile toxin B (TcdB) toxin |
WO2017163808A1 (ja) | 2016-03-22 | 2017-09-28 | 学校法人慶應義塾 | 化合物又はその塩、ナチュラルキラーt細胞活性化剤、及び医薬組成物 |
WO2017207040A1 (en) | 2016-06-01 | 2017-12-07 | Vib Vzw | ANTI-CANCER THERAPY USING A LEPTIN ANTAGONIST AND AN iNKT-CELL ACTIVATOR |
CN106983760A (zh) * | 2017-05-29 | 2017-07-28 | 南京佰泰克生物技术有限公司 | 一种增强肺腺癌细胞对cik细胞杀伤敏感性的组合物 |
US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
CA3201106A1 (en) | 2020-12-04 | 2022-06-09 | Yasuyuki Ishii | Cd1d-ligand-compound-containing liposome preparation having improved pharmacokinetics |
CN114196629B (zh) * | 2021-12-23 | 2024-02-27 | 珠海贝索细胞科学技术有限公司 | 一种高效培养nkt细胞的试剂及其应用和nkt细胞的培养方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK84691D0 (da) * | 1991-05-07 | 1991-05-07 | Karsten Buschard | Visse glycolipider og specifikke catchere for disse til anvendelse ved profylaxe eller terapi af diabetes, og/eller dermed forbundne komplikationer samt anvendelse af saadanne glycolipider til detektion af oe-celle-antistoffer (ica) i et individ og anvendelse af saadanne catchere til detektion af langerhans-oe-celler i pancreas-praeparater |
TW261533B (id) * | 1992-07-16 | 1995-11-01 | Kirin Brewery | |
DE69328435T2 (de) * | 1992-10-22 | 2000-09-14 | Kirin Brewery | Neues sphingolglycolipid und verwendung davon |
JPH06199884A (ja) * | 1992-12-28 | 1994-07-19 | Nisshin Oil Mills Ltd:The | 新規糖脂質誘導体 |
JP4020958B2 (ja) * | 1993-04-15 | 2007-12-12 | キリンファーマ株式会社 | 新規スフィンゴ糖脂質およびその使用 |
JPH1045603A (ja) * | 1996-07-30 | 1998-02-17 | Yoshitomi Pharmaceut Ind Ltd | スルファチドを有効成分とするTNF−α産生抑制剤 |
TW555562B (en) * | 1996-12-27 | 2003-10-01 | Kirin Brewery | Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof |
ATE421881T1 (de) * | 1997-04-10 | 2009-02-15 | Kyowa Hakko Kirin Co Ltd | Nkt-zellenaktivatoren, die alpha-glycosylceramide enthalten |
-
1998
- 1998-04-10 AT AT04030878T patent/ATE421881T1/de not_active IP Right Cessation
- 1998-04-10 JP JP54260598A patent/JP3495740B2/ja not_active Expired - Lifetime
- 1998-04-10 TW TW087105454A patent/TW592703B/zh not_active IP Right Cessation
- 1998-04-10 ID IDW991170A patent/ID23495A/id unknown
- 1998-04-10 CN CNA2005100927032A patent/CN1768759A/zh active Pending
- 1998-04-10 ES ES04030878T patent/ES2318236T3/es not_active Expired - Lifetime
- 1998-04-10 DE DE69840528T patent/DE69840528D1/de not_active Expired - Fee Related
- 1998-04-10 KR KR10-1999-7009253A patent/KR100527950B1/ko not_active IP Right Cessation
- 1998-04-10 EP EP04030878A patent/EP1520583B1/en not_active Expired - Lifetime
- 1998-04-10 ES ES98912758T patent/ES2235324T3/es not_active Expired - Lifetime
- 1998-04-10 DE DE69828603T patent/DE69828603T2/de not_active Expired - Lifetime
- 1998-04-10 WO PCT/JP1998/001657 patent/WO1998044928A1/ja active IP Right Grant
- 1998-04-10 AT AT98912758T patent/ATE286735T1/de not_active IP Right Cessation
- 1998-04-10 CA CA002286482A patent/CA2286482C/en not_active Expired - Lifetime
- 1998-04-10 CN CNB988060884A patent/CN1222293C/zh not_active Expired - Lifetime
- 1998-04-10 EP EP98912758A patent/EP0988860B1/en not_active Expired - Lifetime
-
1999
- 1999-10-12 US US09/402,785 patent/US6531453B1/en not_active Expired - Fee Related
-
2001
- 2001-01-11 HK HK01100286A patent/HK1029526A1/xx not_active IP Right Cessation
-
2003
- 2003-01-02 US US10/334,861 patent/US6747010B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
TW592703B (en) | 2004-06-21 |
AU742253B2 (en) | 2001-12-20 |
CA2286482A1 (en) | 1998-10-15 |
AU6748598A (en) | 1998-10-30 |
CN1768759A (zh) | 2006-05-10 |
EP0988860B1 (en) | 2005-01-12 |
JP3495740B2 (ja) | 2004-02-09 |
EP1520583A2 (en) | 2005-04-06 |
ES2235324T3 (es) | 2005-07-01 |
ES2318236T3 (es) | 2009-05-01 |
DE69828603T2 (de) | 2005-12-29 |
WO1998044928A1 (en) | 1998-10-15 |
EP1520583A3 (en) | 2006-01-25 |
ID23495A (id) | 2000-04-27 |
ATE421881T1 (de) | 2009-02-15 |
EP1520583B1 (en) | 2009-01-28 |
DE69840528D1 (de) | 2009-03-19 |
KR20010006174A (ko) | 2001-01-26 |
CN1222293C (zh) | 2005-10-12 |
EP0988860A4 (en) | 2003-09-03 |
KR100527950B1 (ko) | 2005-11-09 |
US6747010B2 (en) | 2004-06-08 |
US6531453B1 (en) | 2003-03-11 |
CA2286482C (en) | 2008-08-05 |
EP0988860A1 (en) | 2000-03-29 |
CN1259872A (zh) | 2000-07-12 |
DE69828603D1 (de) | 2005-02-17 |
US20030139351A1 (en) | 2003-07-24 |
ATE286735T1 (de) | 2005-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1029526A1 (en) | Nkt cell-activating agents containing alpha-glycosylceramides | |
EP1033981A4 (en) | FORMULATIONS AND METHODS FOR REDUCING THE TOXICITY OF ANTINEOPLASTIC AGENTS | |
IL114829A (en) | Biphenyl isoxazole sulfonamide derivatives and pharmaceutical compositions containing the same | |
IL109615A0 (en) | Polypeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
IL73893A (en) | 11-aryl-13-estradiene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
EP0508488A3 (en) | Use of inositol triphosphate for the treatment of diseases associated with metal intoxications | |
KR0141913B1 (en) | Anti-virus agents | |
EP0456209A3 (en) | Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis | |
ES462103A1 (es) | Procedimiento para la preparacion del derivado yodurado de cloruro de benzalconio. | |
AU626743B2 (en) | Therapeutic application of fluoroquinolone derivatives for pneumocystosis | |
DK0420121T3 (da) | Antitumormiddel | |
IL107614A0 (en) | Vitamin d3 analogs their preparation and pharmaceutical compositions containing them | |
HK56597A (en) | 3-aminochromane derivatives procedure for their preparation and pharmaceutical compositions containing them | |
ES8609286A1 (es) | Un metodo para preparar un compuesto de morfolinol | |
ES8500269A1 (es) | Procedimiento para la fabricacion de un derivado de azolcarboxamida n,n-subsitutida. | |
BE881834A (fr) | Medicaments et preparations pharmaceutiques a activite cytostatique | |
ATE86117T1 (de) | Zusammensetzung gegen leberkrankheiten. | |
GR3000904T3 (en) | Amide derivatives | |
DE69307414D1 (de) | Dipeptidderivate und diese als aktive Bestandteile enthaltendes prophylaktisches oder therapeutisches Mittel gegen Knochenkrankheiten | |
EP1291349A4 (en) | MALTO-OLIGOSACCHARIDE DERIVATIVES AND USE THEREOF | |
IE780526L (en) | Compositions for inhibiting male fertility | |
ATE21908T1 (de) | Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
JPS56118012A (en) | Composition for oral cavity | |
UA23368A (uk) | Використання (1,1-діоксотіолан-3-іл) диктіокарбамату калію як антимікробного засобу | |
KR950016757A (ko) | 약물중독 치료제 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20180409 |